# Array BioPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/array-biopharma

- Industry: Biotechnology
- Headquarters: Boulder, US
- Website: www.arraybiopharma.com
- Total disclosed funding: $8M
- Latest round: Series B (Dec 7, 1999)
- Investors on record: 6

## About

Established in 1998 and based in US, Array BioPharma, Inc. operates as a biopharmaceutical company that provides targeted small molecule drugs. The company cooperates with AstraZeneca, Eli Lilly and Genentech, etc. In 2000, it was listed on the NASDAQ. The company cooperates with Siemens, Fuji Electric and Hager etc. In June 2019, Pfizer Inc. announced to acquire Array BioPharma, Inc.

The company provides targeted small molecule drugs for patients with cancer and other high-burden diseases. Its products include BRAFTOVI® (encorafenib) capsules and MEKTOVI® (binimetinib) tablets. It has over 30 clinical trials, including encorafenib and binimetinib clinical programs.

## Funding rounds

- Series B, Dec 7, 1999, $8M — Advent International, ARCH Venture Partners, Boulder Ventures, Mitsui & Co. USA, Frazier & Company, Falcon Technology Partners

## Investors

- Advent International (https://capitalatlas.ai/funds/advent-international) — Series B
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- Boulder Ventures (https://capitalatlas.ai/funds/boulder-ventures) — Series B
- Mitsui & Co. USA — Series B
- Frazier & Company — Series B
- Falcon Technology Partners (https://capitalatlas.ai/funds/falcon-technology-partners) — Series B